Wei Keat Lim

Wei Keat Lim

Auto-generated profile, based on publicly available information

Wei Keat Lim

Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2011 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
KBKatia Basso
Katia Basso
Lara MussolinLara Mussolin
Lara Mussolin
ALAntonella Lettieri
Antonella Lettieri
MBManisha Brahmachary
Manisha Brahmachary
WLWei Keat Lim
Wei Keat Lim
ARAngelo Rosolen
Angelo Rosolen

20 April 2023 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
KKKaterina Koether
Katerina Koether
VBValérie Besnard
Valérie Besnard
HSHilary Sandig
Hilary Sandig
ACAlan Carruthers
Alan Carruthers
EMElena Miranda
Elena Miranda
BCBruno Crestani
Bruno Crestani
Several reports have highlighted a potential role of autoreactive B-cells and autoantibodies that correlates with increased disease severity in patients with idiopathic pulmonary fibrosis (IPF). Here we show that patients with IPF have an altered B-cell phenotype and that those subjects who have autoantibodies against the intermediate filament protein periplakin (PPL) have a significantly worse outcome in terms of progression-free survival. Using a mouse model of lung fibrosis, we demonstrate that introducing antibodies targeting the endogenous protein PPL (mimicking naturally occurring autoantibodies seen in patients) directly in the lung increases lung injury, inflammation, collagen and fibronectin expression through direct activation of follicular dendritic cells, which in turn activates and drives proliferation of fibroblasts. This fibrocyte population was also observed in fibrotic foci of patients with IPF and was increased in peripheral blood of IPF patients compared to aged-matched controls. This study reiterates the complex and heterogeneous nature of IPF, identifying new pathways that may prove suitable for therapeutic intervention.

18 December 2020 in Science Immunology
Verified
Journal Article
Closed access
PDF file
ZHZaruhi Hovhannisyan
Zaruhi Hovhannisyan
NLNengyin Liu
Nengyin Liu
SKSara Khalil-Aguero
Sara Khalil-Aguero
CPCasandra Panea
Casandra Panea
JVJeffrey VanValkenburgh
Jeffrey VanValkenburgh
SHSokol Haxhinasto
Sokol Haxhinasto
Deficiency in interleukin-36R (IL-36R) antagonist caused by loss-of-function mutations in IL-36RN leads to DITRA (deficiency of IL-36 receptor antagonist), a rare inflammatory human disease that belongs to a subgroup of generalized pustular psoriasis (GPP). We report a functional genetic mouse model of DITRA with enhanced IL-36R signaling analogous to that observed in patients with DITRA, which provides new insight into our understanding of the IL-36 family of molecules in regulating barrier integrity across multiple tissues. Humanized DITRA-like mice displayed increased skin inflammation in a preclinical model of psoriasis, and in vivo blockade of IL-36R pathway using anti-human IL-36R antibody ameliorated imiquimod-induced skin pathology as both prophylactic and therapeutic treatments. Deeper characterization of the humanized DITRA-like mice revealed that deregulated IL-36R signaling promoted tissue pathology during intestinal injury and led to impairment in mucosal restoration in the repair phase of chronic dextran sulfate sodium (DSS)–induced colitis. Blockade of IL-36R pathway significantly ameliorated DSS-induced intestinal inflammation and rescued the inability of DITRA-like mice to recover from mucosal damage in vivo. Our results indicate a central role for IL-36 in regulating proinflammatory responses in the skin and epithelial barrier function in the intestine, suggesting a new therapeutic potential for targeting the IL-36R axis in psoriasis and at the later stages of intestinal pathology in inflammatory bowel disease.

6 September 2024 in Science Immunology
Verified
Journal Article
Closed access
AVAndrea Vecchione
Andrea Vecchione
JDJoseph C. Devlin
Joseph C. Devlin
CTCarley Tasker
Carley Tasker
VRVenkat Raman Ramnarayan
Venkat Raman Ramnarayan
PHPaul Haase
Paul Haase
JOJamie M. Orengo
Jamie M. Orengo
Understanding the phenotypic and transcriptional signature of immunoglobulin E (IgE)–producing cells is fundamental to plasma cell (PC) biology and development of therapeutic interventions for allergy. Here, using a mouse model of intranasal house dust mite (HDM) exposure, we showed that short-lived IgE PCs emerge in lung draining lymph nodes (dLNs) during early exposure (7 weeks). IgE PCs had distinct surface and gene expression profiles in these different tissues compared with other Ig isotypes. IgE BMPCs up-regulated genes associated with prosurvival and BM homing, whereas IgE dLN PCs expressed genes associated with recent class switching and differentiation. IgE PCs also exhibited higher expression of endoplasmic reticulum (ER) stress and protein coding genes and higher antibody secretion rate when compared with IgG1. Overall, this study highlights the unique developmental path and transcriptional signature of short-lived and long-lived IgE PCs.

1 March 2021 in Patterns
Verified
Journal Article
Open access
RZRuoyu Zhang
Ruoyu Zhang
GAGurinder S. Atwal
Gurinder S. Atwal
WLWei Keat Lim
Wei Keat Lim
With the rapid advancement of single-cell RNA-sequencing (scRNA-seq) technology, many data-preprocessing methods have been proposed to address numerous systematic errors and technical variabilities inherent in this technology. While these methods have been demonstrated to be effective in recovering individual gene expression, the suitability to the inference of gene-gene associations and subsequent gene network reconstruction have not been systemically investigated. In this study, we benchmarked five representative scRNA-seq normalization/imputation methods on Human Cell Atlas bone marrow data with respect to their impacts on inferred gene-gene associations. Our results suggested that a considerable amount of spurious correlations was introduced during the data-preprocessing steps due to oversmoothing of the raw data. We proposed a model-agnostic noise-regularization method that can effectively eliminate the correlation artifacts. The noise-regularized gene-gene correlations were further used to reconstruct a gene co-expression network and successfully revealed several known immune cell modules.

15 June 2024 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
KGKaitlyn Gayvert
Kaitlyn Gayvert
MDMartin Desrosiers
Martin Desrosiers
TLTanya M. Laidlaw
Tanya M. Laidlaw
LMLeda P. Mannent
Leda P. Mannent
KPKiran Patel
Kiran Patel
SHSivan Harel
Sivan Harel
There is evidence of pathophysiologic diversity in chronic rhinosinusitis with nasal polyps (CRSwNP), but data characterizing the molecular endotypes of CRSwNP and their association with treatment is lacking. To identify gene signatures associated with CRSwNP endotypes, clinical features, and dupilumab treatment response. Nasal brushing samples were collected from 89 patients randomized to dupilumab 300 mg every 2 weeks or placebo in the SINUS-52 trial (NCT02898454). Microarrays were used to identify transcriptional clusters and assess the relationship between gene expression and baseline clinical features and clinical response to dupilumab. Endotype signatures were determined using differential expression analysis. Two distinct transcriptional clusters (C1 and C2) were identified, both with elevated type 2 biomarkers. At baseline, C2 patients had higher mean Nasal Polyp Score and higher type 2 biomarker levels than C1 patients. At Week 24, significant improvements in clinical outcomes (dupilumab vs placebo) were observed in both clusters, although the magnitude of improvements was significantly greater in C2 than C1, and more C2 patients demonstrated clinically meaningful responses. Gene sets enrichment analyses supported the existence of two molecular endotypes: C2 was enriched in genes associated with type 2 inflammation (including periostin, cadherin-26, and type 2 cysteine protease inhibitors), while C1 was enriched in genes associated with T cell activation and interleukin-12 production. Two distinct gene signatures associated with CRSwNP clinical features were identified; the endotype signatures were associated with clinical outcome measures and magnitude of dupilumab response.